Posts in the “Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer” category:

Bristol-Myers’ oncology star lines up for lung cancer approval, leading the PD-1 pack

Posted by Samantha Powell on September 29th, 2014 |

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb ($BMY) was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs. The company has completed a European application… Read More

Data Confirm Anti-ALK Activity in Rare NSCLC

Posted by Samantha Powell on September 27th, 2014 |

Objective responses occurred in 72% of patients with mutation-specific non-small cell lung cancer (NSCLC) treated with crizotinib (Xalkori), final results from a small clinical trial showed. Median response duration approached 1½ years, and median progression-free survival (PFS) had reached 19.2 months with follow-up ongoing. All 50 patients enrolled in the study had chromosomal rearrangements in… Read More

SBRT Transforms Lives of Many With NSCLC

Posted by Samantha Powell on September 19th, 2014 |

A series of patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) had a 5-year survival of 40% following treatment with stereotactic body radiation therapy (SBRT), results of a cooperative-group trial showed. A fourth of the 59 patients remained alive and disease free after a median follow-up of 48 months. The rate of locoregional… Read More

Patients With NSCLC Who have Never Smoked or Who have Quit Smoking have Lower Risk of Developing Secondary Primary Lung Cancers Than Current Smokers

Posted by Samantha Powell on September 16th, 2014 |

Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today… Read More

NSCLC treatment market estimated to exceed $7.9 billion by 2020

Posted by Samantha Powell on September 14th, 2014 |

The global market value of non-small cell lung cancer treatment will increase from $5.1 billion in 2013 to more than $7.9 billion by 2020 with a compound annual growth rate of 6.6%, according to a report from GBI Research. The company says that this growth will be primarily driven by the introduction of several premium… Read More

Combination microRNA therapy shown to suppress non-small-cell lung cancer

Posted by Samantha Powell on September 5th, 2014 |

BOSTON – Micro RNAs (miRNA) have recently emerged as key therapeutic agents against cancers and are actively being evaluated in pre-clinical models of various cancers as well as in human clinical trials. Now, new findings show that a combination therapy of two miRNAs, let-7 and miR-34, suppressed tumor growth in an animal model of non-small-cell… Read More

Lung Cancer: Higher Rates of Adenocarcinoma Occurring Among Young Females

Posted by Samantha Powell on September 2nd, 2014 |

Although lung cancer incidence is decreasing in the United States, the details about this trend are unknown. Researchers at the National Cancer Institute (NCI) analyzed Surveillance, Epidemiology, and End Results (SEER) data on squamous cell, small cell, adenocarcinoma, large cell, other, and unspecified lung cancers among whites and blacks diagnosed from 1977 to 2010 and… Read More

Herbst Tackles Key Questions in Emerging PD-1/PD-L1 Immunotherapy for NSCLC

Posted by Samantha Powell on August 2nd, 2014 |

Emerging agents and pressing research questions in immunotherapy were reviewed in depth during the 15th Annual International Lung Cancer Congress, with Roy S. Herbst, MD, PhD, of the Yale Cancer Center, leading the way. Herbst was the recipient of the 2014 Addario Lectureship Award, which the Bonnie J. Addario Lung Cancer Foundation bestows annually at… Read More

NCCN Offers Free Webinars for Patients With Non-Small Cell Lung Cancer

Posted by Samantha Powell on July 28th, 2014 |

On Thursday, July 24, 2014, the National Comprehensive Cancer Network® (NCCN®), with the support of the NCCN Foundation®, hosted its first of two free patient information webinars titled, “Know What Your Doctors Know: Non-Small Cell Lung Cancer Treatment.” Registration is still open for the second NCCN patient information webinar, which is scheduled for Saturday, August… Read More

Brachytherapy with Sublobar Resection Fails to Improve NSCLC Recurrence Rates

Posted by Samantha Powell on July 4th, 2014 |

Brachytherapy did not reduce rates of local recurrence after sublobar resection in patients with non–small-cell lung cancer (NSCLC), according to results of a new randomized phase III study. Previous work has suggested an association between sublobar resection and higher locoregional recurrence rates compared with lobectomy; as a result, the procedure is usually reserved for high-risk… Read More